Carisma Therapeutics’ solid tumour therapy obtains FDA Fast Track status

2024-06-26
Pharmaceutical Technology
快速通道临床1期基因疗法细胞疗法
Carisma Therapeutics’ solid tumour therapy obtains FDA Fast Track status
Preview
来源: Pharmaceutical Technology
Participants with unresectable or metastatic solid tumours that overexpress HER2 will be part of the Phase I trial. Credit: Vink Fan via Shutterstock.
Carisma Therapeutics’ solid tumour therapy obtains FDA Fast Track status
Preview
来源: Pharmaceutical Technology
The US Food and Drug Administration (FDA) has granted Fast Track designation for Carisma Therapeutics’ CT-0525 for the treatment of solid tumours overexpressing human epidermal growth factor receptor 2 (HER2).
An ex vivo gene-modified autologous chimeric antigen receptor-monocyte cellular therapy, CT-0525 is being analysed in a Phase I clinical trial.
The open-label trial is designed to assess the safety, tolerability, and manufacturing feasibility of the therapy.
Participants enrolled in the trial will include those with locally advanced (unresectable) or metastatic solid tumours that overexpress HER2 and have advanced following treatment with standard therapies approved presently.
The trial will also feature two dose escalation cohorts to determine the optimal dose of CT-0525.
See Also:AstraZeneca’s Tagrisso receives approval in Japan for lung cancer
Carisma Therapeutics’ solid tumour therapy obtains FDA Fast Track status
Preview
来源: Pharmaceutical Technology
AstraZeneca’s Truqap and Faslodex combo receives approval in EU
Carisma Therapeutics’ solid tumour therapy obtains FDA Fast Track status
Preview
来源: Pharmaceutical Technology
With the receipt of FDA Fast Track status, CT-0525 is now poised for an accelerated review process.
Carisma Therapeutics CMO Eugene Kennedy said: “Receiving Fast Track designation for CT-0525 from the FDA marks a significant milestone for Carisma, highlighting the FDA’s recognition of the serious and life-threatening nature of these malignancies and the potential of CT-0525 to meet this critical medical need.
“We are committed to working closely with the FDA to accelerate the development of CT-0525. Currently, we are enrolling patients in the Phase I clinical trial and remain on track to report initial clinical data by the end of 2024.”
This designation is a significant milestone, intended to expedite the development and review of therapies for serious conditions with unmet medical needs.
In 2022, Carisma Therapeutics and Sesen Bio signed a definitive merger agreement to combine businesses and create a clinical-stage biotechnology company in an all-stock deal.
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.
Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
Free WhitepaperCell and gene therapies: Pipe dream to pipeline
The cell and gene industry is gaining momentum, with a new wave of therapies promising to transform the way doctors treat, and even cure, disease. In this report, Cytiva and GlobalData have collaborated to explore the rise of the cell and gene therapy industries, the current state of the market, present and future opportunities for advancement, and the challenges that lie ahead.
Thank you.You will receive an email shortly. Please check your inbox to download the Whitepaper.
Carisma Therapeutics’ solid tumour therapy obtains FDA Fast Track status
Preview
来源: Pharmaceutical Technology
-->
By downloading this case study, you acknowledge that GlobalData may share your information with Cytiva Thematic and that your personal data will be used as described in their Privacy Policy
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
机构
适应症
靶点
药物
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。